J&J Raises Sales Forecast on Pharmaceutical Growth

The transcript covers Johnson & Johnson's Q2 earnings, highlighting strong performance in pharmaceuticals despite market competition. It discusses strategic acquisitions and dispositions, regulatory impacts on drug pricing, and legal challenges related to talc litigation. The company emphasizes innovation, transparency, and strategic growth to maintain its market position.

What actions has the company taken regarding its portfolio over the past decade?

How does the company view the role of intermediaries in drug spending?

What is the company's stance on the talc litigation?